Brief: Orexo Flagship Pharmaceutical Pipeline Asset OX124 Enters Pivotal Trial

Orexo AB

16/07/2021 07:11

July 16 (Reuters) - Orexo AB  ORX.ST :
    * OREXO'S FLAGSHIP PHARMACEUTICAL PIPELINE ASSET OX124
ENTERS
PIVOTAL TRIAL
    * NEW DRUG APPLICATION (NDA) FILING EXPECTED IN SECOND HALF
OF
2022
    * UPON APPROVAL OREXO WILL ALONG WITH ZUBSOLV® AND MODIA™
HAVE
MOST COMPREHENSIVE RANGE OF TREATMENT OPTIONS FOR PEOPLE
SUFFERING FROM OPIOID USE DISORDER ON US MARKET

Source text for Eikon:  ID:nWkrb3Zjcm 
Further company coverage:  ORX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))